Description

Butanoic Acid, 4-[(2-Methoxyethyl)[4-(5,6,7,8-Tetrahydro-1,8-Naphthyridin-2-Yl)Butyl]Amino]-2-(4-Quinazolinylamino)-, (2S)- is a high-purity, advanced pharmaceutical intermediate with a complex, multi-cyclic structure. This compound is of significant interest for its role as a key building block in the research and development of novel therapeutic agents, particularly in oncology and targeted drug discovery. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and fine chemical manufacturers engaged in the synthesis of sophisticated active pharmaceutical ingredients (APIs).

Application

• Pharmaceutical Intermediate: Critical building block for the synthesis of novel small-molecule drug candidates, particularly in oncology research.
• Kinase Inhibitor Development: Used in the research and production of targeted therapies designed to inhibit specific kinase enzymes involved in cell signaling pathways.
• Preclinical & Clinical Research: Serves as a key material for producing compounds used in pharmacological studies, toxicology assessments, and early-phase clinical trials.
• Chemical Biology Probes: Utilized to create specialized molecular tools for studying biological processes and target validation in drug discovery.
• Custom Synthesis: Supplied to fine chemical companies for custom synthesis projects requiring high-complexity, chiral intermediates.
• Reference Standard: Can be supplied as a high-purity analytical standard for method development and quality control in API manufacturing.

Basic Information

Product Name	Butanoic Acid, 4-[(2-Methoxyethyl)[4-(5,6,7,8-Tetrahydro-1,8-Naphthyridin-2-Yl)Butyl]Amino]-2-(4-Quinazolinylamino)-, (2S)-
CAS No.	2376257-44-0
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	(2S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid; 4-[(2-Methoxyethyl)[4-(5,6,7,8-Tetrahydro-1,8-Naphthyridin-2-Yl)Butyl]Amino]-2-(4-Quinazolinylamino)butanoic Acid (2S)-; (S)-4-((2-Methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; CAS 2376257-44-0; 2376257-44-0; Advanced Kinase Inhibitor Intermediate; Complex Chiral Quinazoline Derivative
EINECS	Contact for details

Quality Control

Our Butanoic Acid, 4-[(2-Methoxyethyl)[4-(5,6,7,8-Tetrahydro-1,8-Naphthyridin-2-Yl)Butyl]Amino]-2-(4-Quinazolinylamino)-, (2S)- is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical characterization using techniques such as HPLC, NMR, and MS to confirm identity, chiral purity, and chemical purity. Certificates of Analysis (COA) detailing all specifications and test results are provided to ensure full traceability and compliance with your research or cGMP requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). This material is hygroscopic (moisture-sensitive); ensure the container is sealed under an inert atmosphere if specified and stored in a low-humidity environment to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 0.5%
Residual Solvents (GC)	Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.